🇺🇸 rtPA in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 12

Most-reported reactions

1. Haemoglobin Decreased — 2 reports (16.67%)
2. Haemorrhage Intracranial — 2 reports (16.67%)
3. Aphasia — 1 report (8.33%)
4. Arrhythmia — 1 report (8.33%)
5. Brain Oedema — 1 report (8.33%)
6. Cardiac Arrest — 1 report (8.33%)
7. Cardiac Failure — 1 report (8.33%)
8. Carotid Arterial Embolus — 1 report (8.33%)
9. Coma — 1 report (8.33%)
10. Condition Aggravated — 1 report (8.33%)

Source database →

Frequently asked questions

Is rtPA approved in United States?

rtPA does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for rtPA in United States?

Hui-Sheng Chen is the originator. The local marketing authorisation holder may differ — check the official source linked above.